Literature DB >> 12688338

Recent progress in the diagnosis and therapy for veno-occlusive disease of the liver.

Kohji Yoshimoto1, Naofumi Ono, Takashi Okamura, Michio Sata.   

Abstract

Veno-occlusive disease (VOD) is one of the severe complications of the liver, which may occur after hematopoietic stem cell transplantation (HSCT). Although an early diagnosis is important to initiate antithrombotic therapy before serious organ failure, the widely used clinical criteria only become clinically fulfilled at an advanced stage of disease. Liver biopsy provides useful findings for the diagnosis of VOD, however, in the later or less severe stages of VOD liver biopsy may provide false-negative sampling error because the biopsy sample may be too small to evaluate the whole liver. In addition it may be difficult to follow the clinical course with repeat biopsy in individual cases. Imaging diagnosis of VOD including gray-scale US, Doppler US, and MRI have been reported as convenient and useful. Color-Doppler US is superior because of its specificity and sensitivity. Blood sampling tests including factor VII, protein C, N-terminal propeptide for type III procollagen (P-III-P) and hyarulonic acid have predictive value, and their measurement may simply be another way to evaluate early hepatic impairment. Since no optimal treatment for VOD has been established as yet, the prophylaxis of VOD or early initiation of treatment is important. These new diagnostic approaches for VOD may provide a direction to resolve the clinical problems of VOD such as the time of initiation of therapy, the therapeutic regimen of choice, and the cessation of therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12688338     DOI: 10.1080/1042819021000029704

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Gallbladder wall oedema and ascites are independent predictors of progression to hepatic veno-occlusive disease for children with hematopoietic stem cell transplantation.

Authors:  Ji Eun Park; Young Hun Choi; Jung-Eun Cheon; Woo Sun Kim; In-One Kim; Young Jin Ryu; Yu Jin Kim; Che Ry Hong; Hyoung Jin Kang
Journal:  Eur Radiol       Date:  2018-01-02       Impact factor: 5.315

2.  Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.

Authors:  Rika Saito; Yasuyuki Kawamoto; Mutsumi Nishida; Takahito Iwai; Yasuka Kikuchi; Isao Yokota; Ryo Takagi; Takahiro Yamamura; Ken Ito; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Naoya Sakamoto
Journal:  Int J Clin Oncol       Date:  2022-08-30       Impact factor: 3.850

3.  A case report of hepatic veno-occlusive disease after ingesting dainties.

Authors:  Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

4.  High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG-99702).

Authors:  Kellie J Nazemi; Violet Shen; Jonathan L Finlay; James Boyett; Mehmet Kocak; Deborah Lafond; Sharon L Gardner; Roger J Packer; H Stacy Nicholson
Journal:  Pediatr Blood Cancer       Date:  2016-05-20       Impact factor: 3.167

Review 5.  Hepatic venous outflow obstruction: three similar syndromes.

Authors:  Ulas-Darda Bayraktar; Soley Seren; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

6.  Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.

Authors:  Masato Nakamura; Tatsuo Kanda; Xia Jiang; Yuki Haga; Koji Takahashi; Shuang Wu; Shin Yasui; Shingo Nakamoto; Osamu Yokosuka
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

Review 7.  Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 2: imaging of complications of cancer treatment.

Authors:  I Zerizer; P D Humphries
Journal:  Cancer Imaging       Date:  2009-11-06       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.